Novo Nordisk A/S (NVO) Stock
NVO Key Statistics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
CEO: Maziar Mike Doustdar. Company website
NVO — Frequently Asked Questions
What is the NVO stock price today?
Novo Nordisk A/S (NVO) trades at $41.09, up 0.96% on the day, as of Nov 12, 2026 09:21 UTC.
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S has a market capitalisation of $181.18B, calculated from the live NVO share price and shares outstanding.
What is the P/E ratio of NVO?
NVO trades at a trailing P/E of 1.62, from earnings per share of $25.43 over the last twelve months.
How much revenue does Novo Nordisk A/S make?
Novo Nordisk A/S generated revenue of $333.14B over the trailing twelve months, which puts the stock at 0.54 times sales.
Does NVO pay a dividend?
Yes. Novo Nordisk A/S pays a dividend yielding 3.06% on the current share price.
What is the 52-week range for NVO?
NVO has traded between $35.13 and $64.16 over the past 52 weeks, and the last price is 36.0% below that high.
Is Novo Nordisk A/S profitable?
Yes. Novo Nordisk A/S keeps 33.92% of revenue as net income over the trailing twelve months.
What is the analyst price target for NVO?
Wall Street analysts rate NVO Buy, with an average price target of $42.33, 3.0% above the current price.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in DK.
Who is the CEO of Novo Nordisk A/S?
Maziar Mike Doustdar is the chief executive of Novo Nordisk A/S, which employs 68,794 people.
Where can I track NVO in real time?
QFI Terminal shows NVO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NVO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NVO in Terminal See plans